Investor Presentation March 2023

TTM Revenue * Composition by Geography & Customer Segments Geography Segments North America EMEA 82% 16% Pacific Rim 2% * DSA contract wins and RMS sales in TTM ending 12/31/22 CRO 41% Government 3% Other 6% Academic 12% Commercial Biopharma 18% Pre-commercial Biopharma 20% 21

View entire presentation